Nous avons fait une sélection d’articles qui peuvent (doivent) intéresser les diabétologues pédiatres amateurs de pompe à insuline (en orangé ceux issus du même groupe, apparemment influenceur). Certains ont été commentés dans les Actualités et le Blog du site.

1. Brown SA, Beck RW, Raghinaru D, et al. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2020 Aug;43(8):1822-1828.
2. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Diabetes Technol Ther. 2021 May;23(5):342-349. Sur le site : L’essai International Diabetes Closed-Loop.
3. Kanapka LG, Wadwa RP, Breton MD, et al. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. Diabetes Care. 2021 Feb;44(2):473-478. Sur le site : Suite du Système Control-IQ en boucle fermée.
4. Kudva YC, Laffel LM, Brown S, et al. Patient Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed Loop Trial. Diabetes Technol Ther. 2021 Jun 11.
5. O’Malley G, Messer LH, Levy CJ, et al. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. Diabetes Technol Ther. 2021 Apr;23(4):245-252.
6. Kovatchev B, Anderson SM, Raghinaru D, et al. Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care. 2020 Mar;43(3):607-615.
7. Cobry EC, Kanapka LG, Cengiz E, et al. Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. Diabetes Technol Ther. 2021 Jun;23(6):401-409. Sur le site : Qualité de vie et contrôle en boucle fermée.
8. Schoelwer MJ, Kanapka LG, Wadwa RP, et al. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. Diabetes Technol Ther. 2021 Jul;23(7):475-481.
9. Bisio A, Brown SA, McFadden R, et al. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. Pediatr Diabetes. 2021 May;22(3):495-502.
10. Pinsker JE, Müller L, Constantin A, et al. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology. Diabetes Technol Ther. 2021 Feb;23(2):120-127.
11. Kovatchev BP, Kollar L, Anderson SM, et al. Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. Lancet Digit Health. 2020 Feb;2(2):e64-e73. Sur le site : Boucle fermée versus pompes «senseur-augmentées» dans la nuit.
12. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Apr 21.
13. Messer LH, Berget C, Ernst A, et al. Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic. Pediatr Diabetes. 2021 Jun;22(4):586-593. Sur le site : Initiation de la boucle fermée hybride.
14. Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021 Jan 16;397(10270):208-219. Sur le site : Système hybride expérimental Medtronic : l’essai FLAIR.
15. Amadou C, Franc S, Benhamou PY, et al. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. Diabetes Care. 2021 Mar;44(3):844-846.